Skip to main content
Premium Trial:

Request an Annual Quote

Swiss Functional Genomics Center Licenses Rosetta s Resolver

NEW YORK, Nov. 21 (GenomeWeb News) - The Functional Genomics Center of Zurich, Switzerland, has licensed the Rosetta Resolver gene expression-analysis system, Rosetta said today.


The center will use the system to analyze and store cross-platform microarray data generated from its regional functional genomic projects.


The Rosetta Resolver is developed and supported by Rosetta Biosoftware and is distributed exclusively by Agilent Technologies. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics, a wholly owned subsidiary of Merck.


Financial details were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.